Efficacy of secukinumab in the treatment of moderatesevere plaque psoriasis at a tertiary care teaching hospital in India

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Mavoori Archana; Pamar Sneha; Bala Sudha

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: IRANIAN JOURNAL OF DERMATOLOGY Year:2021 | Volume:24 | Issue:4 Page(s): 255-261

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Efficacy of secukinumab in the treatment of moderatesevere plaque psoriasis at a tertiary care teaching hospital in India

Author(s)

Mavoori Archana | Pamar Sneha | Bala Sudha | Issue Writer Certificate

Keywords

biologic therapy

psoriasis

psoriatic arthritis

Abstract

Background: Secukinumab is a fully humanized IL-17A antagonist approved for managing moderate-to-severe plaque psoriasis as well as psoriatic arthritis. This study assessed the speed of action of secukinumab and the improvement in the quality of life in a series of patients. Methods: We aimed to assess changes in the PASI (Psoriasis Area Severity Index) and DLQI (Dermatology Life Quality Index) following a course of secukinumab injections. Methods: This hospital-based study was conducted in the Department of Dermatology, Venereology and Leprosy of ESIC Medical College & Hospital, Hyderabad, India. Results: Starting from 8 weeks after initiation of treatment with secukinumab 300 mg, a clinically significant response was observed, with progressive reduction of skin disease indices. Twenty-four patients were included in the study, with a mean age of 42 years. The male to female ratio was 15: 9. Thirteen (54. 16%) patients achieved PASI 75 at eight weeks. At the end of 52 weeks, 20 (83. 33%), 15 (62. 5%), and 8 (33. 33%) patients maintained PASI 75, PASI 90, and PASI 100, respectively. Conclusion: Secukinumab is a highly-efficacious, biologic therapy that provides rapid relief with a relatively favorable safety profile in patients with moderate-severe plaque psoriasis. In addition, secukinumab is a preferred treatment for patients with comorbid psoriatic arthritis or arthralgia symptoms due to its ability to arrest the progression of arthritic disease in the early course.

Multimedia

No record.

Cites

No record.

References

No record.

Cite

APA: Copy

Mavoori, Archana, Pamar, Sneha, & Bala, Sudha. (2021). Efficacy of secukinumab in the treatment of moderatesevere plaque psoriasis at a tertiary care teaching hospital in India. IRANIAN JOURNAL OF DERMATOLOGY, 24(4), 255-261. SID. https://sid.ir/paper/1033338/en

Vancouver: Copy

Mavoori Archana, Pamar Sneha, Bala Sudha. Efficacy of secukinumab in the treatment of moderatesevere plaque psoriasis at a tertiary care teaching hospital in India. IRANIAN JOURNAL OF DERMATOLOGY[Internet]. 2021;24(4):255-261. Available from: https://sid.ir/paper/1033338/en

IEEE: Copy

Archana Mavoori, Sneha Pamar, and Sudha Bala, “Efficacy of secukinumab in the treatment of moderatesevere plaque psoriasis at a tertiary care teaching hospital in India,” IRANIAN JOURNAL OF DERMATOLOGY, vol. 24, no. 4, pp. 255–261, 2021, [Online]. Available: https://sid.ir/paper/1033338/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops